391 related articles for article (PubMed ID: 19805105)
1. A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane.
Mandelker D; Gabelli SB; Schmidt-Kittler O; Zhu J; Cheong I; Huang CH; Kinzler KW; Vogelstein B; Amzel LM
Proc Natl Acad Sci U S A; 2009 Oct; 106(40):16996-7001. PubMed ID: 19805105
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α.
Echeverria I; Liu Y; Gabelli SB; Amzel LM
FEBS J; 2015 Sep; 282(18):3528-42. PubMed ID: 26122737
[TBL] [Abstract][Full Text] [Related]
3. Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.
Hon WC; Berndt A; Williams RL
Oncogene; 2012 Aug; 31(32):3655-66. PubMed ID: 22120714
[TBL] [Abstract][Full Text] [Related]
4. Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.
Huang CH; Mandelker D; Gabelli SB; Amzel LM
Cell Cycle; 2008 May; 7(9):1151-6. PubMed ID: 18418043
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA).
Burke JE; Perisic O; Masson GR; Vadas O; Williams RL
Proc Natl Acad Sci U S A; 2012 Sep; 109(38):15259-64. PubMed ID: 22949682
[TBL] [Abstract][Full Text] [Related]
6. Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase alpha (PI3Kalpha ). Functions of lipid kinase-deficient PI3Kalpha in signaling.
Pirola L; Zvelebil MJ; Bulgarelli-Leva G; Van Obberghen E; Waterfield MD; Wymann MP
J Biol Chem; 2001 Jun; 276(24):21544-54. PubMed ID: 11278889
[TBL] [Abstract][Full Text] [Related]
7. Biophysical aspect of phosphatidylinositol 3-kinase and role of oncogenic mutants (E542K & E545K).
Kalsi N; Gopalakrishnan C; Rajendran V; Purohit R
J Biomol Struct Dyn; 2016 Dec; 34(12):2711-2721. PubMed ID: 26646651
[TBL] [Abstract][Full Text] [Related]
8. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.
Huang CH; Mandelker D; Schmidt-Kittler O; Samuels Y; Velculescu VE; Kinzler KW; Vogelstein B; Gabelli SB; Amzel LM
Science; 2007 Dec; 318(5857):1744-8. PubMed ID: 18079394
[TBL] [Abstract][Full Text] [Related]
9. Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kα.
Liu X; Zhou Q; Hart JR; Xu Y; Yang S; Yang D; Vogt PK; Wang MW
Proc Natl Acad Sci U S A; 2022 Nov; 119(46):e2215621119. PubMed ID: 36343266
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit.
Miled N; Yan Y; Hon WC; Perisic O; Zvelebil M; Inbar Y; Schneidman-Duhovny D; Wolfson HJ; Backer JM; Williams RL
Science; 2007 Jul; 317(5835):239-42. PubMed ID: 17626883
[TBL] [Abstract][Full Text] [Related]
11. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.
Sun M; Hillmann P; Hofmann BT; Hart JR; Vogt PK
Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15547-52. PubMed ID: 20713702
[TBL] [Abstract][Full Text] [Related]
12. Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.
Zhao L; Vogt PK
Cell Cycle; 2010 Feb; 9(3):596-600. PubMed ID: 20009532
[TBL] [Abstract][Full Text] [Related]
13. Engineering of an isolated p110α subunit of PI3Kα permits crystallization and provides a platform for structure-based drug design.
Chen P; Deng YL; Bergqvist S; Falk MD; Liu W; Timofeevski S; Brooun A
Protein Sci; 2014 Oct; 23(10):1332-40. PubMed ID: 25043846
[TBL] [Abstract][Full Text] [Related]
14. Regulation of the p85/p110alpha phosphatidylinositol 3'-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains.
Yu J; Wjasow C; Backer JM
J Biol Chem; 1998 Nov; 273(46):30199-203. PubMed ID: 9804776
[TBL] [Abstract][Full Text] [Related]
15. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in
Dornan GL; Siempelkamp BD; Jenkins ML; Vadas O; Lucas CL; Burke JE
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1982-1987. PubMed ID: 28167755
[TBL] [Abstract][Full Text] [Related]
16. Capitalizing on tumor genotyping: towards the design of mutation specific inhibitors of phosphoinsitide-3-kinase.
Gabelli SB; Duong-Ly KC; Brower ET; Amzel LM
Adv Enzyme Regul; 2011; 51(1):273-9. PubMed ID: 21035489
[TBL] [Abstract][Full Text] [Related]
17. Investigating the structure and dynamics of the PIK3CA wild-type and H1047R oncogenic mutant.
Gkeka P; Evangelidis T; Pavlaki M; Lazani V; Christoforidis S; Agianian B; Cournia Z
PLoS Comput Biol; 2014 Oct; 10(10):e1003895. PubMed ID: 25340423
[TBL] [Abstract][Full Text] [Related]
18. A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase.
Dbouk HA; Pang H; Fiser A; Backer JM
Proc Natl Acad Sci U S A; 2010 Nov; 107(46):19897-902. PubMed ID: 21030680
[TBL] [Abstract][Full Text] [Related]
19. Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions.
Hao Y; Wang C; Cao B; Hirsch BM; Song J; Markowitz SD; Ewing RM; Sedwick D; Liu L; Zheng W; Wang Z
Cancer Cell; 2013 May; 23(5):583-93. PubMed ID: 23643389
[TBL] [Abstract][Full Text] [Related]
20. Structural basis of nSH2 regulation and lipid binding in PI3Kα.
Miller MS; Schmidt-Kittler O; Bolduc DM; Brower ET; Chaves-Moreira D; Allaire M; Kinzler KW; Jennings IG; Thompson PE; Cole PA; Amzel LM; Vogelstein B; Gabelli SB
Oncotarget; 2014 Jul; 5(14):5198-208. PubMed ID: 25105564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]